CRISPR-based and alternative gene editing platforms (TALENs, zinc fingers, base and prime editors); services spanning design, in vitro and in vivo editing, off-target characterization, process development, and GMP-ready manufacturing. Integrated regulatory support, validated analytics, and a unified digital QMS (ALCOA+) ensure that every program is audit-ready by design.

A deliberate approach to gene editing

Gene editing is rapidly redefining medicine, agriculture, and industrial biotechnology. From CRISPR-driven cell therapies to TALEN-modified crops and zinc finger-based diagnostics, the applications are multiplying. Yet most providers offer only fragments of the workflow—plasmid supply here, in vitro screening there—with little integration across design, editing, and characterization. MycoVista fills this gap.

We treat gene editing not as an experiment but as an engineered system. Each CRISPR CDMO program begins with rational design and predictive modeling, advances through validated editing and off-target profiling, and concludes with regulatory-grade data packages suitable for IND, IMPD, or BLA submissions. This seamless continuum transforms risk into control and makes timelines more predictable.

Why teams run CRISPR CDMO programs here

Programs in gene editing often fail because sponsors are forced to navigate multiple vendors without harmonized methods or data. We eliminate that fragmentation with an integrated offering:

• End-to-end ownership: gRNA and nuclease design, editing workflow optimization, off-target screening, potency characterization, GMP-scale production, fill–finish, and stability programs—all within one unified QMS.
• Editing platforms supported: CRISPR-Cas9, CRISPR-Cas12/13, TALENs, zinc fingers, and emerging base/prime editors. Sponsors don’t have to choose a path in isolation—we support platform evaluation and cross-comparison.
• Closed-system readiness: All editing workflows, whether in vitro or ex vivo, are engineered for reproducibility in closed manufacturing platforms, minimizing operator risk and variability.
• Regulatory fluency: IND/IMPD/BLA text authored from validated methods and real data, not generic templates. Our regulatory files read as coherent narratives that map design to control strategy.

This is why clients seeking CRISPR CDMO support bring their programs to MycoVista: we collapse design, execution, and compliance into one auditable spine.

Background: Challenges that actually matter

Most CDMOs touch gene editing lightly, but the true challenges require depth:

• Design complexity. Guide RNAs and nucleases must be optimized for specificity, efficiency, and manufacturability. Many failures trace back to design choices made without downstream consideration. At MycoVista, we treat design as a process parameter, quantifying on-target versus off-target tradeoffs and modeling outcomes before committing to runs.
• Editing reproducibility. Whether ex vivo (e.g., T cells, NK cells) or in vitro (e.g., functional assays), editing conditions must survive scale-up. We build DoEs around MOI, editing window, repair template design, and delivery mode (RNP, mRNA, viral) to ensure reproducibility.
• Characterization depth. Off-target detection is not optional. We deploy both unbiased genome-wide assays and targeted panels, tied to acceptance criteria. This is baked into the CQA stack, not treated as an afterthought.
• Regulatory clarity. Programs collapse when comparability protocols are improvised midstream. Our CRISPR CDMO programs define comparability in advance, making scale, site, or platform transitions defensible.

Program spine: QTPP → CQAs → CPPs

Every CRISPR CDMO engagement is structured around measurable definitions of success.

QTPP (target product): intended therapeutic indication or application (human therapy, agricultural trait, diagnostic reagent), editing window, acceptable on-target efficiency, maximum allowable off-target profile, presentation format (vials, syringes), sterility and endotoxin limits, and stability requirements.

CQAs (measured attributes): editing efficiency (on-target %), specificity (off-target profile by unbiased assay plus targeted confirmation), potency in mechanism-specific assays, viability post-editing (if ex vivo), residual vector or nuclease, sterility, endotoxin, and stability readouts.

CPPs (controlled parameters): gRNA sequence and structure, nuclease format (mRNA, protein, plasmid), delivery method (RNP electroporation, lipid, viral), MOI, editing window, repair template design, buffer composition, and culture conditions.

This linkage from QTPP to CQA to CPP ensures that our clients’ CRISPR CDMO programs are inspection-ready and reproducible.

Editing modalities and delivery systems

Our team supports the full range of editing technologies:

• CRISPR nucleases: Cas9, Cas12, Cas13, with variations for high fidelity, reduced PAM dependency, or RNA targeting.
• TALENs and zinc fingers: Still valuable for certain specificity or regulatory contexts.
• Base and prime editors: Emerging platforms for precise nucleotide changes without double-strand breaks.

Delivery methods are matched to phase and application: electroporation, lipid nanoparticles, viral vectors, or hybrid systems. Each is qualified for efficiency, reproducibility, and regulatory acceptance.

Analytics and characterization

In gene editing, credibility is defined by the quality of data. Regulators, clinicians, and even investors now demand clear evidence that editing outcomes are not only effective but also safe, reproducible, and mechanistically understood. Too often, programs collapse not because the edit failed, but because the analytical package lacked depth or consistency. MycoVista approaches analytics as the foundation of every CRISPR CDMO program, ensuring that design choices and process parameters are linked directly to data. By building orthogonal panels and enforcing clear acceptance criteria, we eliminate ambiguity and provide sponsors with regulatory-grade evidence.

Our CRISPR CDMO analytics platform spans every stage of the workflow, integrating modern sequencing, cell-based assays, and stability studies into a single, auditable stack. Importantly, we do not treat analytics as a secondary service. Instead, each assay is positioned where it informs a decision—whether it is vector design, editing optimization, comparability, or release testing.

• On-target analysis: We verify that the intended genetic modification is achieved with high precision. Deep sequencing provides comprehensive readouts of on-target changes, while droplet digital PCR (ddPCR) delivers sensitive, quantitative confirmation. Functional assays, tailored to the biological mechanism, translate genetic data into clear demonstrations of therapeutic relevance.
• Off-target analysis: No gene editing program can be credible without rigorous off-target profiling. We deploy unbiased methods such as GUIDE-seq, DISCOVER-seq, and CIRCLE-seq, supplemented by computational predictions. Orthogonal confirmation is always performed to reduce false positives and anchor conclusions in data that regulators trust.
• Potency assays: Every therapeutic has a unique mechanism, so potency assays cannot be generic. We build mechanism-specific readouts—cell killing for oncology applications, cytokine release for immunotherapies, metabolic changes for engineered enzymes, or trait-expression panels for agricultural programs. These assays are qualified to phase-appropriate standards and scaled for reproducibility.
• Release testing: We integrate sterility, endotoxin, mycoplasma, and residual nuclease/vector assays into every program, not as late-stage checks but as critical quality attributes. Each method is tied back to the QTPP, ensuring clarity at submission and inspection.
• Stability programs: We design stability studies around real-world logistics, not abstract templates. Real-time and accelerated programs map degradation pathways for editing reagents, delivery vectors, and edited cells. We track viability, potency, and off-target drift across relevant storage and shipping conditions.

By weaving these analytics into every stage, MycoVista ensures that gene editing programs not only advance but also withstand the most rigorous scrutiny.

Facilities and scale

Capabilities matter, but transparency about scale and control is what separates an ordinary service provider from a true CRISPR CDMO partner. MycoVista invests in infrastructure that supports both cutting-edge science and regulatory durability. Our facilities are designed with the explicit goal of making cell and gene editing programs reproducible at every stage—pilot, clinical, and commercial.

We run closed-system workflows for ex vivo editing of CAR-T, NK, and stem cells, minimizing operator risk and contamination while enabling consistent expansion kinetics. In parallel, we offer scalable in vitro editing platforms for diagnostics, agriculture, and industrial biotech, capable of producing large reagent lots under GMP conditions.

• Cleanrooms: Our hubs feature ISO 8/7 cleanrooms with validated positive-pressure flows. Utilities—high-purity water, clean steam, and compressed air—are qualified and trended, ensuring that every lot is produced under controlled, compliant conditions.
• Analytics suites: We house integrated sequencing platforms, ddPCR/qPCR instruments, multiparameter flow cytometry, potency assay labs, and specialized off-target detection setups. These suites are fully connected to our digital infrastructure, allowing every data point to be traceable to the batch record.
• Digital systems: We operate eBMR/eBR, ELN, LIMS, and CDS under validated environments with controlled access and audit trails. Data integrity is enforced through ALCOA+ principles, making regulatory inspections straightforward.

By sizing capabilities to sponsor needs while preserving auditability, we provide a pathway from feasibility to global commercialization without unnecessary tech transfer disruptions.

Regulatory and QMS posture

The regulatory bar for gene editing is uniquely high. Agencies expect sponsors not only to prove that edits are effective but also to show that off-target risks are controlled, comparability is prespecified, and data integrity is uncompromised. Programs that rely on patchwork vendors often fail this test because their data lacks continuity and their documentation is inconsistent.

At MycoVista, regulatory readiness is embedded from the first conversation. Our CRISPR CDMO philosophy is “audit-ready by design”—meaning we build control strategies, batch records, and data systems with inspection in mind. This prevents sponsors from scrambling to retrofit documentation later.

• QbD alignment: Every design choice is mapped to supporting data, every data set is mapped to the process, and every process is reflected in the batch record. This linear alignment makes reviewer questions easy to answer with evidence, not adjectives.
• Digital QMS: Deviation, CAPA, change control, investigations, and training records all reside in a unified system across hubs. This eliminates gaps, accelerates responses, and creates a coherent regulatory file.
• Comparability: We prespecify comparability protocols for scale, site, or platform changes, ensuring that sponsors can adapt without jeopardizing filings. Orthogonal confirmations are included where they materially reduce risk.
• Authoring: IND/IMPD/BLA content is drafted from validated data tables and statistical plans, not vague narrative. Our regulatory writing team ensures that submissions read as logical extensions of the process, not as retrofitted justifications.

This is what makes MycoVista a CRISPR CDMO that regulators trust: clarity, continuity, and control.

Program onboarding (first 30 days)

Timelines in gene editing are unforgiving, and early missteps compound downstream. That’s why we front-load clarity. Our onboarding process ensures that sponsors have a roadmap with explicit decision gates, risks identified, and data expectations defined.

Within the first 30 days, every client receives:

• QTPP → CQA → CPP mapping: Explicit definitions of the intended product, attributes to be measured, and process levers to control them.
• DoE plan: Covering gRNA/nuclease design, editing conditions, off-target analytics, and delivery methods.
• Risk register and Gantt chart: With decision gates tied directly to IND/IMPD/BLA milestones, giving sponsors transparency on cost, risk, and timeline.
• Regulatory roadmap: Outlining the exact data packages needed for each phase and how they will be generated under our digital QMS.

This structured onboarding minimizes rework, prevents misalignment, and sets programs on a trajectory to succeed in both biology and regulatory review.

Technical FAQ: CRISPR CDMO

1. Which CRISPR platforms do you support?
We support CRISPR-Cas9, Cas12, Cas13, TALENs, zinc fingers, and emerging base and prime editors, with validated workflows for both research and GMP contexts.

2. Do you design and optimize gRNAs?
Yes. We use computational modeling and experimental validation to design guide RNAs with high on-target efficiency and minimized off-target potential, with traceable design-to-data linkage.

3. How do you quantify editing efficiency?
On-target efficiency is measured using deep sequencing, ddPCR, and functional assays. Assays are phase-appropriate and validated for reproducibility.

4. How do you evaluate off-target edits?
We deploy unbiased methods like GUIDE-seq, DISCOVER-seq, and CIRCLE-seq, coupled with computational predictions and orthogonal confirmations, ensuring regulatory credibility.

5. What delivery systems do you provide?
We support RNP electroporation, mRNA delivery, viral vectors, and lipid nanoparticle systems. Platform choice is tailored to therapeutic indication, scalability, and regulatory requirements.

6. Can you handle ex vivo editing for cell therapies?
Yes. We run closed-system workflows for CAR-T, NK, TCR-T, and stem cell editing with reproducible activation, expansion, transduction, and cryopreservation protocols.

7. Do you support in vitro editing for diagnostics and agriculture?
Yes. We offer scalable in vitro editing workflows for diagnostic reagents, research tools, and agricultural applications, supported by GMP documentation where required.

8. How do you manage comparability during scale-up?
Comparability protocols are prespecified, with acceptance criteria defined up front. Orthogonal analytics confirm sameness across site, scale, or platform changes.

9. Do you offer plasmid or vector supply for editing workflows?
Yes. We integrate plasmid DNA and viral vector manufacturing with editing programs, aligning vector specifications to transduction efficiency and potency assays.

10. How are potency assays designed?
Assays are customized to therapeutic mechanism—cell killing, cytokine release, metabolic activity, or trait validation—and validated for reproducibility.

11. How do you control batch-to-batch variability?
CPPs are tightly defined (MOI, editing window, repair template format, buffer conditions). Batch records and operator settings are locked with audit trails under our digital QMS.

12. What stability studies do you provide?
We conduct real-time and accelerated stability programs for reagents, vectors, and edited cells, tracking potency, viability, and degradation pathways relevant to logistics.

13. Do you support base and prime editing?
Yes. We have exploratory and development-stage workflows for base and prime editors, with QTPP–CQA–CPP frameworks designed for regulatory scalability.

14. How do you ensure regulatory compliance for IND/IMPD/BLA submissions?
All regulatory sections are authored from validated data and protocols, with explicit QTPP–CQA–CPP mapping, orthogonal confirmations, and comparability strategies included.

15. Do you run closed-system manufacturing for GMP?
Yes. Editing workflows are engineered into closed-system footprints with automated tubing, integrated bioreactors, and aseptic fill–finish platforms, minimizing operator risk.

16. How do you manage data integrity?
All assays and processes are managed under a validated digital QMS (ALCOA+), with controlled access, audit trails, and electronic batch records.

17. Can you support custom off-target panels for regulators?
Yes. We develop bespoke targeted off-target panels based on in silico predictions, clinical context, and regulatory guidance, supported by unbiased orthogonal data.

18. What cleanroom capabilities do you have?
We operate ISO 8/7 cleanrooms with validated utilities (HPW, clean steam, compressed air) sized for clinical and commercial gene editing programs.

19. Do you support both R&D and GMP phases?
Yes. We transition programs from discovery to IND-enabling studies and into GMP manufacturing, with comparability bridges that make each step auditable.

20. What does “audit-ready by design” mean in practice?
It means every decision—design, assay, process, or scale—is mapped to data, written into batch records, and stored under our digital QMS, so inspection questions can be answered with evidence, not adjectives.

Summary

CRISPR and related gene editing technologies are reshaping entire industries—from oncology and rare disease therapy to agriculture and diagnostics. But innovation alone is not enough. Success requires engineered control, reproducible analytics, and audit-ready systems. MycoVista provides the full continuum of CRISPR CDMO services: design, editing, characterization, and manufacturing, all built into closed systems and aligned with regulatory frameworks.

The result is a product that is not just functional, but defensible. A process that is not only innovative, but reproducible. And a filing package that can withstand the most demanding inspections. For sponsors seeking a partner who can deliver clarity, speed, and regulatory strength, MycoVista is the CRISPR CDMO of choice.

Contact our team today at info@mycovistabiotech.com